{
    "Rank": 163,
    "Study": {
        "ProtocolSection": {
            "IdentificationModule": {
                "NCTId": "NCT00653250",
                "OrgStudyIdInfo": {
                    "OrgStudyId": "VICC THO 0055"
                },
                "SecondaryIdInfoList": {
                    "SecondaryIdInfo": [
                        {
                            "SecondaryId": "P50CA090949",
                            "SecondaryIdType": "U.S. NIH Grant/Contract",
                            "SecondaryIdLink": "https://reporter.nih.gov/quickSearch/P50CA090949"
                        },
                        {
                            "SecondaryId": "P30CA068485",
                            "SecondaryIdType": "U.S. NIH Grant/Contract",
                            "SecondaryIdLink": "https://reporter.nih.gov/quickSearch/P30CA068485"
                        },
                        {
                            "SecondaryId": "VU-VICC-THO-0055"
                        },
                        {
                            "SecondaryId": "VU-VICC-000724"
                        }
                    ]
                },
                "Organization": {
                    "OrgFullName": "Vanderbilt-Ingram Cancer Center",
                    "OrgClass": "OTHER"
                },
                "BriefTitle": "Celecoxib in Treating Patients With Stage I, Stage II, or Stage IIIA Non-Small Cell Lung Cancer",
                "OfficialTitle": "COX-2 Activity in Early and Advanced NSCLC and The Effect of Short-Term Administration of Specific COX-2 Inhibitors (Celecoxib)"
            },
            "StatusModule": {
                "StatusVerifiedDate": "May 2013",
                "OverallStatus": "Completed",
                "ExpandedAccessInfo": {
                    "HasExpandedAccess": "No"
                },
                "StartDateStruct": {
                    "StartDate": "December 2000"
                },
                "PrimaryCompletionDateStruct": {
                    "PrimaryCompletionDate": "March 2006",
                    "PrimaryCompletionDateType": "Actual"
                },
                "CompletionDateStruct": {
                    "CompletionDate": "January 2008",
                    "CompletionDateType": "Actual"
                },
                "StudyFirstSubmitDate": "April 3, 2008",
                "StudyFirstSubmitQCDate": "April 3, 2008",
                "StudyFirstPostDateStruct": {
                    "StudyFirstPostDate": "April 4, 2008",
                    "StudyFirstPostDateType": "Estimate"
                },
                "LastUpdateSubmitDate": "May 20, 2013",
                "LastUpdatePostDateStruct": {
                    "LastUpdatePostDate": "May 21, 2013",
                    "LastUpdatePostDateType": "Estimate"
                }
            },
            "SponsorCollaboratorsModule": {
                "ResponsibleParty": {
                    "ResponsiblePartyType": "Principal Investigator",
                    "ResponsiblePartyInvestigatorFullName": "Vicki Keedy, MD",
                    "ResponsiblePartyInvestigatorTitle": "Assistant Professor of Medicine, Medical Oncologist",
                    "ResponsiblePartyInvestigatorAffiliation": "Vanderbilt-Ingram Cancer Center"
                },
                "LeadSponsor": {
                    "LeadSponsorName": "Vanderbilt-Ingram Cancer Center",
                    "LeadSponsorClass": "OTHER"
                },
                "CollaboratorList": {
                    "Collaborator": [
                        {
                            "CollaboratorName": "National Cancer Institute (NCI)",
                            "CollaboratorClass": "NIH"
                        }
                    ]
                }
            },
            "OversightModule": {
                "OversightHasDMC": "Yes"
            },
            "DescriptionModule": {
                "BriefSummary": "RATIONALE: Studying samples of tissue, blood, and urine from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.\n\nPURPOSE: This clinical trial is studying celecoxib in treating patients with stage I, stage II, or stage IIIA non-small cell lung cancer.",
                "DetailedDescription": "OBJECTIVES:\n\nTo assess cyclo-oxygenase-2 (COX-2) activity in patients with early-stage non-small cell lung cancer (NSCLC) and correlate the results with serum vascular endothelial growth factor (VEGF) levels, tumor microvessel density score, tumor prostaglandin E2 (PGE_2) and matrix metalloproteinases (MMP) levels, and the major urinary metabolite of PGE_2, PGE-M.\nTo assess the effect of specific COX-2 inhibitors (celecoxib) on COX-2 expression within the primary tumor, serum VEGF levels and tumor microvascular density, tumor PGE_2 and MMP levels, and urinary PGE-M in a cohort of patients with early-stage NSCLC.\n\nOUTLINE: Patients receive oral celecoxib 400 mg twice a day for 5 days in the absence of disease progression or unaccepted toxicity. Patients with early-stage disease then undergo surgery.\n\nBiopsy, serum, and urine samples are obtained at baseline and after celecoxib treatment. The biopsy specimen are examined for the expression of cyclo-oxygenase-2 (COX-2), PGE_2, and selected MMPs by immunohistochemistry, western blotting, and northern blotting. Serum and urine samples are analyzed for VEGF and PGE-M expression. COX-2 tumor expression is correlated with serum VEGF levels; tumor MMP-2, MMP-9, and PGE_2 expression; urinary PGE-M and microvessel density scores."
            },
            "ConditionsModule": {
                "ConditionList": {
                    "Condition": [
                        "Lung Cancer"
                    ]
                },
                "KeywordList": {
                    "Keyword": [
                        "stage I non-small cell lung cancer",
                        "stage II non-small cell lung cancer",
                        "stage IIIA non-small cell lung cancer"
                    ]
                }
            },
            "DesignModule": {
                "StudyType": "Interventional",
                "PhaseList": {
                    "Phase": [
                        "Not Applicable"
                    ]
                },
                "DesignInfo": {
                    "DesignAllocation": "N/A",
                    "DesignInterventionModel": "Single Group Assignment",
                    "DesignPrimaryPurpose": "Treatment",
                    "DesignMaskingInfo": {
                        "DesignMasking": "None (Open Label)"
                    }
                },
                "EnrollmentInfo": {
                    "EnrollmentCount": "22",
                    "EnrollmentType": "Actual"
                }
            },
            "ArmsInterventionsModule": {
                "ArmGroupList": {
                    "ArmGroup": [
                        {
                            "ArmGroupLabel": "Therapeutic Intervention",
                            "ArmGroupType": "Experimental",
                            "ArmGroupDescription": "Correlative",
                            "ArmGroupInterventionList": {
                                "ArmGroupInterventionName": [
                                    "Drug: celecoxib",
                                    "Procedure: biopsy",
                                    "Procedure: therapeutic conventional surgery"
                                ]
                            }
                        }
                    ]
                },
                "InterventionList": {
                    "Intervention": [
                        {
                            "InterventionType": "Drug",
                            "InterventionName": "celecoxib",
                            "InterventionDescription": "400 mg P.O. BID for five days prior to obtaining second serum/urine collection (starting after initial biopsy, serum and urine collection)",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Therapeutic Intervention"
                                ]
                            },
                            "InterventionOtherNameList": {
                                "InterventionOtherName": [
                                    "celebrex"
                                ]
                            }
                        },
                        {
                            "InterventionType": "Procedure",
                            "InterventionName": "biopsy",
                            "InterventionDescription": "in patients with newly diagnosed NSCLC, a pretreatment excision of a small amount of tumor tissue",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Therapeutic Intervention"
                                ]
                            }
                        },
                        {
                            "InterventionType": "Procedure",
                            "InterventionName": "therapeutic conventional surgery",
                            "InterventionDescription": "surgery to remove the lung tumor",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Therapeutic Intervention"
                                ]
                            },
                            "InterventionOtherNameList": {
                                "InterventionOtherName": [
                                    "tumor resection"
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomesModule": {
                "PrimaryOutcomeList": {
                    "PrimaryOutcome": [
                        {
                            "PrimaryOutcomeMeasure": "Correlation of expression of cyclo-oxygenase-2 (COX-2) activity with serum VEGF levels, tumor microvessel density score, tumor PEG2 and MMP levels, and urinary PGE-M",
                            "PrimaryOutcomeDescription": "COX-2 will be measured in pre-treatment tumor biopsy tissue as well as tumor microvessel density, MMP-2 and PGE2. VEGF will be measured in pre-treatment blood.",
                            "PrimaryOutcomeTimeFrame": "Date of pretreatment biopsy surgery (tissue) and day 1 (blood)"
                        }
                    ]
                },
                "SecondaryOutcomeList": {
                    "SecondaryOutcome": [
                        {
                            "SecondaryOutcomeMeasure": "Effect of Celecoxib on COX-2 expression and microvascular density in tumor, PGE2 and MMP levels in tumor, serum VEGF levels and urinary PGE-M",
                            "SecondaryOutcomeDescription": "Patients with early-stage NSCLC will undergo tumor resection after 5 days of treatment with celecoxib. Tumor tissue will be examined. Post-treatment blood and urine will also be collected and examined.",
                            "SecondaryOutcomeTimeFrame": "After day 5 of 5 days of treatment"
                        }
                    ]
                }
            },
            "EligibilityModule": {
                "EligibilityCriteria": "DISEASE CHARACTERISTICS:\n\nPresumed histological or cytological diagnosis of non-small cell lung cancer\n\nDiagnosis to be confirmed upon study entry to collect biopsy material for correlative studies\nStage I-IIIA disease\n\nPATIENT CHARACTERISTICS:\n\nECOG performance status of 0-2\nSerum creatinine \u2264 1.5 mg/dL\nGranulocytes \u2265 1,500/mm^3\nPlatelets \u2265 100,000/mm^3\nAST \u2264 3 times normal\nBilirubin \u2264 1.5 mg/dL\nNot pregnant or nursing\nFertile patients must use effective contraception\nNo active unresolved infection\n\nPRIOR CONCURRENT THERAPY:\n\nAt least 7 days since prior and no concurrent non-steroidal anti-inflammatory agents or other cyclo-oxygenase-2 inhibitors\nAt least 7 days since prior parenteral antibiotics\nNo prior systemic chemotherapy or radiotherapy",
                "HealthyVolunteers": "No",
                "Gender": "All",
                "StdAgeList": {
                    "StdAge": [
                        "Child",
                        "Adult",
                        "Older Adult"
                    ]
                }
            },
            "ContactsLocationsModule": {
                "OverallOfficialList": {
                    "OverallOfficial": [
                        {
                            "OverallOfficialName": "Vicki Keedy, MD",
                            "OverallOfficialAffiliation": "Vanderbilt-Ingram Cancer Center",
                            "OverallOfficialRole": "Principal Investigator"
                        }
                    ]
                }
            }
        },
        "DerivedSection": {
            "MiscInfoModule": {
                "VersionHolder": "September 08, 2023"
            },
            "ConditionBrowseModule": {
                "ConditionMeshList": {
                    "ConditionMesh": [
                        {
                            "ConditionMeshId": "D000008175",
                            "ConditionMeshTerm": "Lung Neoplasms"
                        }
                    ]
                },
                "ConditionAncestorList": {
                    "ConditionAncestor": [
                        {
                            "ConditionAncestorId": "D000012142",
                            "ConditionAncestorTerm": "Respiratory Tract Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000013899",
                            "ConditionAncestorTerm": "Thoracic Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000009371",
                            "ConditionAncestorTerm": "Neoplasms by Site"
                        },
                        {
                            "ConditionAncestorId": "D000009369",
                            "ConditionAncestorTerm": "Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000008171",
                            "ConditionAncestorTerm": "Lung Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000012140",
                            "ConditionAncestorTerm": "Respiratory Tract Diseases"
                        }
                    ]
                },
                "ConditionBrowseLeafList": {
                    "ConditionBrowseLeaf": [
                        {
                            "ConditionBrowseLeafId": "M10862",
                            "ConditionBrowseLeafName": "Lung Neoplasms",
                            "ConditionBrowseLeafAsFound": "Lung Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M5236",
                            "ConditionBrowseLeafName": "Carcinoma, Non-Small-Cell Lung",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M14669",
                            "ConditionBrowseLeafName": "Respiratory Tract Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M16348",
                            "ConditionBrowseLeafName": "Thoracic Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M10858",
                            "ConditionBrowseLeafName": "Lung Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M14667",
                            "ConditionBrowseLeafName": "Respiratory Tract Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "ConditionBrowseBranchList": {
                    "ConditionBrowseBranch": [
                        {
                            "ConditionBrowseBranchAbbrev": "BC04",
                            "ConditionBrowseBranchName": "Neoplasms"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC08",
                            "ConditionBrowseBranchName": "Respiratory Tract (Lung and Bronchial) Diseases"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "All",
                            "ConditionBrowseBranchName": "All Conditions"
                        }
                    ]
                }
            },
            "InterventionBrowseModule": {
                "InterventionMeshList": {
                    "InterventionMesh": [
                        {
                            "InterventionMeshId": "D000068579",
                            "InterventionMeshTerm": "Celecoxib"
                        }
                    ]
                },
                "InterventionAncestorList": {
                    "InterventionAncestor": [
                        {
                            "InterventionAncestorId": "D000000894",
                            "InterventionAncestorTerm": "Anti-Inflammatory Agents, Non-Steroidal"
                        },
                        {
                            "InterventionAncestorId": "D000018712",
                            "InterventionAncestorTerm": "Analgesics, Non-Narcotic"
                        },
                        {
                            "InterventionAncestorId": "D000000700",
                            "InterventionAncestorTerm": "Analgesics"
                        },
                        {
                            "InterventionAncestorId": "D000018689",
                            "InterventionAncestorTerm": "Sensory System Agents"
                        },
                        {
                            "InterventionAncestorId": "D000018373",
                            "InterventionAncestorTerm": "Peripheral Nervous System Agents"
                        },
                        {
                            "InterventionAncestorId": "D000045505",
                            "InterventionAncestorTerm": "Physiological Effects of Drugs"
                        },
                        {
                            "InterventionAncestorId": "D000000893",
                            "InterventionAncestorTerm": "Anti-Inflammatory Agents"
                        },
                        {
                            "InterventionAncestorId": "D000018501",
                            "InterventionAncestorTerm": "Antirheumatic Agents"
                        },
                        {
                            "InterventionAncestorId": "D000052246",
                            "InterventionAncestorTerm": "Cyclooxygenase 2 Inhibitors"
                        },
                        {
                            "InterventionAncestorId": "D000016861",
                            "InterventionAncestorTerm": "Cyclooxygenase Inhibitors"
                        },
                        {
                            "InterventionAncestorId": "D000004791",
                            "InterventionAncestorTerm": "Enzyme Inhibitors"
                        },
                        {
                            "InterventionAncestorId": "D000045504",
                            "InterventionAncestorTerm": "Molecular Mechanisms of Pharmacological Action"
                        }
                    ]
                },
                "InterventionBrowseLeafList": {
                    "InterventionBrowseLeaf": [
                        {
                            "InterventionBrowseLeafId": "M277",
                            "InterventionBrowseLeafName": "Celecoxib",
                            "InterventionBrowseLeafAsFound": "Locally",
                            "InterventionBrowseLeafRelevance": "high"
                        },
                        {
                            "InterventionBrowseLeafId": "M26699",
                            "InterventionBrowseLeafName": "Cyclooxygenase 2 Inhibitors",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M3907",
                            "InterventionBrowseLeafName": "Anti-Inflammatory Agents",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M3908",
                            "InterventionBrowseLeafName": "Anti-Inflammatory Agents, Non-Steroidal",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M3722",
                            "InterventionBrowseLeafName": "Analgesics",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M20476",
                            "InterventionBrowseLeafName": "Analgesics, Non-Narcotic",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M20294",
                            "InterventionBrowseLeafName": "Antirheumatic Agents",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M18899",
                            "InterventionBrowseLeafName": "Cyclooxygenase Inhibitors",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M7641",
                            "InterventionBrowseLeafName": "Enzyme Inhibitors",
                            "InterventionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "InterventionBrowseBranchList": {
                    "InterventionBrowseBranch": [
                        {
                            "InterventionBrowseBranchAbbrev": "Infl",
                            "InterventionBrowseBranchName": "Anti-Inflammatory Agents"
                        },
                        {
                            "InterventionBrowseBranchAbbrev": "ARhu",
                            "InterventionBrowseBranchName": "Antirheumatic Agents"
                        },
                        {
                            "InterventionBrowseBranchAbbrev": "Analg",
                            "InterventionBrowseBranchName": "Analgesics"
                        },
                        {
                            "InterventionBrowseBranchAbbrev": "All",
                            "InterventionBrowseBranchName": "All Drugs and Chemicals"
                        }
                    ]
                }
            }
        }
    }
}